Scores
Name: SCORES
A phase 2 open label multicentre study assessing the safety tolerability pharmacokinetics and preliminary anti-tumour activity of MED14736 in combination with AZD9150 or AZD5069 in patients with advanced solid malignancies and subsequently comparing AZD9150 and AZD5069 both as monotherapy and in combination with MED14736 as second line treatment inpatients with recurrent and /or metastatic SCC of the head & neck.
Acronym:
SCORES
Summary & Eligibility:
Based on the patients history of treatment with an anti PD-L1 antibody, the patient will be randomly assigned of one of 6 arms (whether prior exposure or no exposure to anti PD-L1)
Inclusion Criteria
To be eligible, all of the following inclusion criteria must be met:
- Aged 18 years or above.
- ECOG performance status of 0 or 1
- Measurable disease for RESIST
- Has had <3 previous treatments
- Has adequate blood values
Exclusion Criteria
The patient is ineligible if any one of the following exclusion criteria are met:
- Had spinal cord compression
- Has a 2nd malignancy
- Completed previous cancer therapy < 4 weeks.
- Suffers from a co-morbidity that the investigator renders the patient unsuitable for participation in the study.
- Has a history of TB
Status:
Open
Sponsor:
AstraZenica
Study Coordinator:
Ashley Campbell
Oncology Buisness Unit INC Research
River View,
The meadows Buisness Park
Station Approach
Camberley
Surrey
GU17 9AE
